Early Breast Cancer · Breast Conservation vs Mastectomy + Axilla
Conservable → BCS + whole-breast radiotherapy (survival equal to mastectomy) + SLNB (Z0011); contraindicated → mastectomy; large/triple-negative/HER2+ → neoadjuvant downstaging.
Mastectomy (± reconstruction): BCS contraindicated → mastectomy (± immediate/delayed reconstruction; skin-/nipple-sparing for selected cases); axilla likewise SLNB first …
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).
Full pathway
- [Decision] Is BCS feasible (contraindications?) + axilla/subtypeIs breast conservation feasible (any contraindication) + axillary status + molecular subtype?
- Conservable (unifocal, negative margins achievable, radiotherapy possible) → BCS + whole-breast radiotherapy + SLNB
- BCS contraindicated (multicentric/diffuse malignant calcification/cannot achieve negative margins/first-second trimester or prior chest-wall radiation/inflammatory cancer) → Mastectomy (± reconstruction)
- Large/locally advanced tumor, triple-negative or HER2+ (consider neoadjuvant downstaging) → Neoadjuvant downstaging
- [End] BCS + whole-breast radiotherapy + SLNBConservable → breast-conserving surgery (BCS/lumpectomy, negative margins) + whole-breast radiotherapy (survival equal to mastectomy); axilla: clinically N0 → sentinel lymph node biopsy (SLNB); per Z0011: cT1-2 + BCS + whole-breast radiotherapy with 1–2 positive SLNs may omit axillary dissection.
- [End] Mastectomy (± reconstruction)BCS contraindicated → mastectomy (± immediate/delayed reconstruction; skin-/nipple-sparing for selected cases); axilla likewise SLNB first (clinically N0); adjuvant radiotherapy (chest wall/regional) as indicated.
- [End] Neoadjuvant downstagingLarge/locally advanced or triple-negative/HER2+ → neoadjuvant chemotherapy (± anti-HER2 targeted) to downstage, aiming for conservation and assessing pathologic complete response; after treatment, BCS or mastectomy by response + axillary management (cN+ often axillary dissection or targeted axillary surgery).
Source guidelines & references
- Local management of early breast cancer (NCCN; SSO-ASTRO margins; ACOSOG Z0011 axilla)
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.